Tryp Therapeutics Submits IND Application for Phase 2a Clinical Trial in FibromyalgiaIrwin Naturals Bringing Its Household Name Brand to the Psychedelic Mental Health SpaceTryp Therapeutics Announces Inclusion in AdvisorShares Psychedelics ETFMindMed and Liechti Lab Provide Results from their Psilocybin R&D CollaborationPsyched Wellness Announces Inclusion in AdvisorShares Psychedelics Exchange Traded Fund (ETF)Tryp Therapeutics Submits IND Application for Phase 2a Clinical Trial in Eating DisordersPsyched Wellness Initiates a Clinical Sleep Study on Humans for a Structure/Function Claim For AME-1Mindset Pharma Selects Treatment-Resistant Depression and End of Life Cancer Angst as Indications for MSP-1014, its NoveHow Will The Data Protection Ruling On Ketamine Impact Psychedelic Novel Drug Development Moving Forward?Mindset Pharma Announces its Next Generation Novel 5-MeO-DMT Psychedelic AnalogsSilo Pharma Advances Psychedelic Patent PortfolioTryp Therapeutics Completes Psychotherapy Training for Phase 2a Study at the University of FloridaMajor Psychedelic Clinical Trial Data Is Right Around The CornerPsychedelic Drug Development Companies Are Leveraging Bolt On MedTech Acquisitions To Create A More Robust Patient Care 7 Psychedelic Clinical Trials Underway That Investors Should Keep On Their RadarNuminus Wellness Closes Q3 2021 With $63.2 Million Cash Position, Lab and Trial Advances, and Strategic Expansion into PSilo Pharma Awarded Notice of Allowance from United States Patent and Trademark Office for Homing Peptide PatentTryp Therapeutics Announces Q3 2021 Financial ResultsKetamine One’s IRP Clinic Using Innovative NeuroCatch Platform to Measure Brain Function in Injured VeteransWake Network, Inc. and the Lieber Institute for Brain Development Announce Research Collaboration

Technical420 Site Search

Returned 11 result(s).

Rritual Announces Successful Completion of Second Full Scale Manufacturing Run and Commencement of Third Full Scale Manufacturing Run in Early April

Rritual Superfoods Inc. (CSE: RSF) (CSE: RSF.WT) is pleased to provide an update on its upcoming US retail launch of its plant-based superfood elixirs. Rritual has successfully completed a second commercial scale manufacturing run which is approximately  50% larger than its initial production run.  Production for early April is scheduled and…

Rritual Superfoods Announces Closing of Initial Public Offering

Rritual Superfoods Inc. (CSE: RSF; RSF.WT) announced that it has closed its previously announced initial public offering and raised total gross proceeds of $6,000,000. On February 26, 2021, the Company obtained a receipt for its final prospectus filed with the securities regulatory authorities in each of the provinces of Canada…

Numinus Wellness (TSXV:NUMI) To Begin Trading Today On The TSX Venture Exchange

So far this year, the psychedelic industry has been a bright spot in what has been a challenging market. We like to compare the emergence of the psychedelic industry to the cannabis industry and believe that it is an opportunity to be aware of. Many of the companies that are…

MindMed Acquires Exclusive License to Eight Clinical Trials of LSD, Partners with World-Leading Psychedelic Research Laboratory at University Hospital Basel

Multi-year deal gives MindMed access to largest collection of clinical trials & knowhow for LSD psychedelic research including a Phase 2 clinical trial of LSD for the treatment of anxiety. Mushroom Stocks ‍ Basel, Switzerland (April 1, 2020): Mind Medicine (MindMed) Inc. (NEO: MMED OTC: MMEDF), the leading neuro-pharmaceutical company for…

Empower Clinics to Create Psilocybin and Psychadelics Division Leveraging Corporate Wellness Clinics and Franchise Clinic Network

EMPOWER CLINICS INC. (CSE:CBDT)(OTC:EPWCF)(Frankfurt:8EC) ("Empower" or the "Company"), a vertically integrated and growth-oriented life sciences company is pleased to announce it intends to leverage its existing clinic network, the developing franchise brand, its 165,000 patients and product development capability, to create psilocybin and psychedelics subsidiaries. The Company has been conducting…

YIELD GROWTH Subsidiary Flourish Mushroom Labs Appoints Neurologist and Psychiatrist Dr. William Panenka as Chair of the Medical Advisory Board

 The Yield Growth Corp. (CSE: BOSS) (OTCQB: BOSQF) (FSE: YG3) announces its subsidiary Flourish Mushroom Labs Inc. has appointed Dr. William Panenka, MD, MSc, FRCPC (Neurology and Psychiatry) as Chair of its Medical Advisory Board. Figure 1: Neurologist and Psychiatrist Dr. William Panenka Appointed as Chair of the Flourish Mushroom Labs Medical…

YIELD GROWTH Subsidiary Flourish Mushroom Labs Announces Agreement to Establish Laboratory to Grow and Research Psilocybin Mushrooms

The Yield Growth Corp. (CSE: BOSS) (OTCQB: BOSQF) (FSE: YG3) announces its subsidiary Flourish Mushroom Labs Inc. entered into a binding letter of intent on January 4, 2020 with Acres Agricultural Canada Corp. ("Acres") to jointly form a company in Saint Vincent and the Grenadines, Acres Flourish Labs (SVG) Ltd. ("AF…

CBD and Functional Mushrooms Could Be Major Catalysts For The Yield Growth Corporation In 2020

During the last year, we have been following a number of high-growth trends that are expected to continue in 2020 and at the same time have been working to identify companies that are levered to such trends. From cannabis to edible mushrooms, we have seen a significant increase in the…

YIELD GROWTH Subsidiary Flourish Mushroom Labs Files for U.S. Patent to use Serotonin Antagonists from Psychedelic Mushrooms for Weight Loss

The Yield Growth Corp. (CSE: BOSS) (OTCQB: BOSQF) (FSE: YG3) announces its subsidiary Flourish Mushroom Labs has filed a U.S. provisional patent application in the United States for the invention relating to methods of using serotonin antagonists, in particular, psychedelic mushroom actives, for weight loss. Image: Psychedelic Mushrooms To view an…

Will Yield Growth’s Bet On The Billion Dollar Edible Mushroom Market Pay Off In 2020?

During the last year, we have been following a number of high-growth trends that are expected to continue in 2020 and at the same time have been working to identify companies that are levered to such trends. From cannabis to edible mushrooms, we have seen a significant increase in the…

Older Posts »

Search Again

The psychedelics sector is starting to take off as smart money begins to position itself across the industry.

Stay updated with all latest updates,upcoming events & much more.
Subscribe
SUBSCRIBE NOW
close-link